Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing
11 janv. 2023 02h00 HE
|
Valo Therapeutics LTD
HELSINKI, Finland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it...
Novotech Acquires European CRO – Strengthens Global Operations
09 janv. 2023 11h33 HE
|
Novotech
SINGAPORE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Novotech announced today the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important...
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
09 janv. 2023 10h33 HE
|
First Light Acquisition Group; Calidi Biotherapeutics, Inc.
-Total gross proceeds from transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and...
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2023
09 janv. 2023 07h00 HE
|
Shattuck Labs, Inc.
AUSTIN, TX & DURHAM, NC, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer
09 janv. 2023 07h00 HE
|
Ractigen Therapeutics
SUZHOU, China, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been appointed Chief Operating Officer of the Company. "I am thrilled to...
Health Care Consulting Leader Monument Analytics Will Change Its Name to Stage Analytics™
05 janv. 2023 09h00 HE
|
Stage Analytics™
ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Health care consulting leader Monument Analytics announces that it has changed its name to Stage Analytics™. The new name captures the importance of...
Persbericht Biocartis Group NV: Openbaarmaking van transparantiekennisgevingen
04 janv. 2023 11h40 HE
|
Biocartis NV
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE4 januari 2023, 17:40 CET Openbaarmaking van transparantiekennisgevingen Mechelen, België, 4 januari 2023 – Biocartis Group NV (de ‘Vennootschap’...
Press release Biocartis Group NV: Disclosure of transparency notifications
04 janv. 2023 11h40 HE
|
Biocartis NV
PRESS RELEASE: REGULATED INFORMATION 4 January 2023, 17:40 CET Disclosure of transparency notifications Mechelen,...
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
04 janv. 2023 08h00 HE
|
Immutep Limited
SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3...
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...